New shot shows promise for severe eczema sufferers
NCT ID NCT07445919
First seen Mar 08, 2026 · Last updated May 10, 2026 · Updated 5 times
Summary
This study tests an experimental drug called SM17, given as a shot under the skin, for people with moderate-to-severe atopic dermatitis (eczema). About 200 adults aged 18 to 70 will receive either SM17 or a placebo to see if it safely reduces eczema severity and improves symptoms over 16 weeks. The goal is to find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.